GNCA Genocea Biosciences (NASDAQ) $0.0001 on 26 Feb 2026: Top loser signals to watch
GNCA stock collapsed to $0.0001 on 26 Feb 2026 as trading closed on the NASDAQ in the United States. The drop of -97.44% from the prior close reflects near-zero liquidity and lingering fallout from Genocea Biosciences, Inc.’s Chapter 11 reorganization and prolonged clinical uncertainty. Volume was 30,268 shares versus a 50-day average price of $0.00 and a 200-day average of $0.11, underscoring thin trading. This piece breaks down the drivers, key ratios, Meyka AI grade, and a short-term forecast to help investors assess GNCA stock risk and any possible recovery scenarios.
Price collapse and trading facts for GNCA stock
Genocea Biosciences, Inc. (GNCA) closed at $0.0001 on NASDAQ on 26 Feb 2026 after opening at $0.0007 and a previous close of $0.0039. The one-day price change recorded -97.44%, with 30,268 shares traded versus an average volume of 80,568.
Year-to-date and multi‑period returns show extreme deterioration: the 1‑year change is -99.99% and the 3‑month change is -98.31%. Market capitalization is reported effectively as $0.00, reflecting minimal public float and potential delisting or microcap status risks.
What pushed GNCA stock lower
The price collapse links to Genocea’s Chapter 11 filing in July 2022 and stalled clinical programs, which eroded investor confidence. Ongoing liquidity constraints and lack of visible near‑term revenue left GNCA stock highly sensitive to any negative update.
Regulatory and operational headwinds remain material. The company’s pipeline progress for GEN‑009 and GEN‑011 has not produced clear commercial catalysts, and clinical setbacks historically have driven sharp downside in biotech microcaps.
Financials and key metrics relevant to GNCA stock
Recent key metrics show cash per share $0.54, book value per share $0.39, and negative net income per share -$0.22 (TTM). Current ratio is 2.24, suggesting short‑term liquidity is present on the balance sheet but insufficient to restore market confidence given operating cash burn.
Price averages are weak: 50‑day average $0.00 and 200‑day average $0.11. Enterprise value is listed negative in the data, which reflects reporting oddities at near‑zero market cap. Investors should note the high research and development spend rate at 23.78% of revenue, emphasizing a research‑heavy cost base.
Meyka AI rates GNCA with a score out of 100
Meyka AI rates GNCA with a score out of 100: 62.62 — Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry checks, financial growth, key metrics, forecast signals, analyst consensus where available, and broader fundamental growth.
This grade does not guarantee performance and is informational only. Given GNCA stock’s low price and prior reorganization, the grade reflects a mix of residual asset value and elevated execution risk in biotech development.
Technical view, price targets and GNCA stock forecast
Technical indicators are unreliable with GNCA stock at $0.0001 due to minimal liquidity and extreme price gaps. For practical planning, we use scenario price targets: bear $0.0001, base $0.0010, bull $0.0100 (all USD). These reflect recovery tied to binary clinical or corporate events.
Meyka AI’s forecast model projects a 12‑month base target of $0.0010. Compared with the current price $0.0001, that implies an implied upside of 900.00%. Forecasts are model‑based projections and not guarantees; downside to $0.0001 remains a realistic scenario without positive catalysts.
Risks, sector context and trading strategy for GNCA stock
GNCA is in the Healthcare sector, Biotechnology industry, which has shown higher volatility versus broader markets. Sector M&A and clinical readouts can produce outsized moves, but that also increases downside risk for small caps like Genocea.
For traders we advise tight position sizing, limit orders, and awareness of delisting or suspension risk. For longer‑term investors, prioritize corporate developments, cash runway updates, and any restructuring outcomes. See company updates at Genocea website and recent reporting on the reorganization Reuters for background. Also consult our GNCA hub on Meyka for live tracking: Meyka GNCA page.
Final Thoughts
GNCA stock’s close at $0.0001 on 26 Feb 2026 marks it among the NASDAQ top losers on the day, driven by historical Chapter 11 concerns, thin liquidity, and stalled clinical progress. Financials show modest cash per share ($0.54) and a current ratio of 2.24, but persistent net losses and research spending maintain high execution risk. Meyka AI rates GNCA 62.62/100 (Grade B, HOLD), balancing remaining asset value against operational uncertainty. Meyka AI’s forecast model projects a 12‑month base target of $0.0010 (implied upside 900.00% versus the current price $0.0001). These forecasts are model‑based projections and not guarantees. Key takeaways: the stock is highly speculative, downside to the current level is possible without catalysts, and any recovery hinges on concrete clinical or restructuring milestones. Investors should use strict risk controls and follow updates from Genocea and trusted news sources before adding GNCA stock to a portfolio.
FAQs
Why did GNCA stock fall to $0.0001
GNCA stock fell due to Genocea’s Chapter 11 reorganization history, stalled clinical catalysts, and very low liquidity. These factors created strong selling pressure and price gaps that pushed shares to $0.0001.
What is Meyka AI’s grade for GNCA stock
Meyka AI rates GNCA 62.62/100, Grade B, Suggestion HOLD. The grade uses benchmark, sector, financial growth, metrics, forecasts and analyst signals; it is informational, not investment advice.
What is the 12‑month GNCA stock forecast
Meyka AI’s forecast model projects a base 12‑month target of $0.0010, implying 900.00% upside versus the current $0.0001. Forecasts are model‑based projections and not guarantees.
What are the main risks for GNCA stock
Main risks include potential delisting, continued clinical trial failures, cash burn, and low trading liquidity. Any of these can keep GNCA stock near current lows or push it lower.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.